New Tampa, Fla., Manufacturer Launches Deep UV LED Medical Device for Treating Psoriasis, Eczema, Vitiligo
TAMPA, Fla. (Aug. 11, 2011) - Tampa, Fla. manufacturer, Psoria‐Shield™ Inc., has announced the launch of sales for its flagship medical device, the Psoria‐Light (FDA 510k #K103540). The Psoria‐Light™ is a Deep UV LED targeted phototherapy device for treating psoriasis, eczema, vitiligo and other UV‐treatable skin disorders.
The Psoria‐Light™ patent‐pending innovation uses advanced Deep UV LED technology originally developed for NASA, ESA, and the U.S. military. Psoria‐Light™ targeted UV phototherapy technology is exclusively recognized as a Certified Space Technology by the Space Foundation.
Psoria‐Light™ offers the same narrow‐band UVB light region, dosage and small treatment spot size as excimer laser‐based targeted UV phototherapy devices. Psoria‐Light™ delivers both NB‐UVB and UVA light to treat skin disorders.
Psoria‐Shield™ was established in 2009 with the goal of creating less toxic non‐invasive treatment options for patients suffering from UV‐treatable skin disorders. President and Founder Scot Johnson, a medical device design engineer, has been developing cutting‐edge medical devices within the Tampa Bay area for over 16 years.
Psoria‐Light™ is currently sold to dermatologists and qualified healthcare providers, but not for personal use at home. Targeted UV phototherapy generally facilitates clearance of skin conditions within 6 to 10 treatments, and up to five times faster than non‐targeted UV phototherapy treatment currently available. Targeted UV phototherapy has only a local effect on the skin, and is a less toxic treatment option than many of the biologic and systemic treatments currently being utilized to treat psoriasis, eczema and vitiligo.
Dr. Seth Forman, a Tampa based dermatologist, will be the first in the Tampa Bay area to provide Psoria‐Light™ treatment to his patients.
Patients interested in finding treatment in their area can visit: http://www.psoria-shield.com/how-get-psoria-light-treatment.
Psoria‐Shield advocates the use of targeted UV phototherapy to address those aspects of patients' disease which reduce their Quality of Life the most, first. By addressing the major detractors from patients' Quality of Life initially, patients and healthcare providers can address the remaining regions of skin with less aggressive therapy.
Lux Dynamics LLC